跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
VENLAFAXINA RETARD DAVURGAMA 150 MG CAPSULAS DE LIBERACION PROLONGADA - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
VENLAFAXINA RETARD DAVURGAMA 150 MG CAPSULAS DE LIBERACION PROLONGADA
Approved
STANDARD
VENLAFAXINA RETARD DAVURGAMA 150 MG CAPSULAS DE LIBERACION PROLONGADA
Teva Pharma S.L.U.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Jul 1, 2022
Approval ID
7e8671d31f63266b
Company
Teva Pharma S.L.U.
Type
Standard
Approval Details
Approval Id
7e8671d31f63266b
Drug Cima Aemps Name
VENLAFAXINA RETARD DAVURGAMA 150 MG CAPSULAS DE LIBERACION PROLONGADA
Register Number
87922
Holder Company Name
Teva Pharma S.L.U.
Marketing Company Name
Teva Pharma S.L.U.
Authorization Date
2022-07-01
Dosage Form
CÁPSULA DURA DE LIBERACIÓN PROLONGADA
Dose
150 mg
Route Of Administration
VÍA ORAL
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
No
Company Name
Teva Pharma S.L.U.
Active Ingredients
VENLAFAXINA HIDROCLORURO
170,5 mg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Jul 1, 2022
Approval ID
7e8671d31f63266b
Type
Standard
Back to CIMA-AEMPS Approvals